Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)

HIV Infection Clinical Trial

Official title:

Feasibility Study of a Once Daily Antiretroviral Regimen for HIV-Infected Patients With CD4 Below 200/mm3, in Hô Chi Minh City, Vietnam

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00158470
• Other study ID #: ANRS 1210 VIETAR
• Secondary ID: VIETAR
• Status: Completed
• Phase: Phase 3
• First received: September 7, 2005
• Last updated: July 2, 2007
• Start date: September 2003
• Est. completion date: May 2007

Study information

• Verified date: July 2007
• Source: French National Agency for Research on AIDS and Viral Hepatitis
• Contact: n/a
• Is FDA regulated: No
• Health authority: Vietnam: Ho Chi Minh City Health Service
• Study type: Interventional

Clinical Trial Summary

Access to care and treatment using antiretroviral drugs will be expanded in Vietnam in the next few years. The ANRS 1210 study is a pilot program to evaluate the feasibility of a simplified antiretroviral treatment using three antiretroviral drugs once a day. The objectives will be to assess the efficacy and the tolerance of this treatment and to better understand the difficulties linked to social and behavioural conditions of patients at different stages during the treatment.

Description:

Despite a high number of infected subjects (estimated of 250,000 at the end of 2004) and a rapid spread of HIV infection in Vietnam, the use of anti-retroviral therapy remains limited. However, access to care and treatment will be expanded in Vietnam in the next few years with the support of national and international organisations. ANRS 1210 study is the first pilot program using highly active antiretroviral therapy (HAART) to evaluate the efficacy and the tolerance of an antiretroviral therapy delivered to adults in an external system of medical care, in Ho Chi Minh City. This feasibility study has also the objective to evaluate the cause of treatment failures and to assess social and behavioural conditions of patients at different stages during the treatment.

The present study is an open trial with direct individual benefit. The chosen treatment is a once-daily administration of 3TC, ddI and Efavirenz delivered to HIV infected adults with a CD4 count below 200/mm3. The duration of the study is eighteen months with a main evaluation at six months. One hundred patients will be selected in outpatient consultation of Binh Trieu hospital and Tropical Diseases Hospital of Ho Chi Minh City. The main criteria of evaluation will be the immunological response at 6 months, opportunistic infection events and the proportion of patients undergoing a regular monitoring at 6 months. Viral response will be also appreciated but, for technical question, will not be a main criteria of the study.

Patients are also administered a questionnaire by a trained independent interviewer about adherence to treatment, mental well-being, housing and nutrition, drug and sexual behaviour, social support and disclosure in order to study the associations between sociobehavioural dimensions, adherence and viral load at two successive follow-up visits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: May 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Man or woman over 18 years old

• HIV infected

• Written informed consent signed

• CD4 count lower than 200/mm3

• No previous antiretroviral treatment

• Weight over 45 kilos and/or body mass index over 16

• Karnofsky Index over or equal to 70 percent

Exclusion Criteria:

• Pregnant woman or woman without effective contraception

• Opportunistic infection compromising the realisation of the treatment

• Tumoral pathology

• Progressive psychiatric affection

• Previous history of peripheral neuropathy or pancreatitis

• Hemoglobin above 90 g/l

• PMN neutrophil above 1.0G/l

• Platelets above 50G/l

• Liver enzymes over 5 times the normal values

• Lipase and/or amylase over 2 times the normal values

• Prothrombin rate above 50 percent

• Plasmatic creatinine over 200 micromoles/l

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infection
• HIV Infections

Intervention

Drug:
• efavirenz

• didanosine

• lamivudine

Locations

Country	Name	City	State
Vietnam	Binh Trieu Hospital	Ho Chi Minh City
Vietnam	Tropical Diseases Hospital	Ho Chi Minh City

Sponsors (1)

Lead Sponsor	Collaborator
French National Agency for Research on AIDS and Viral Hepatitis

Country where clinical trial is conducted

Vietnam, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CD4 lymphocyte count after HAART		6 months
Secondary	Evaluation of treatment failures causes		12 months
Secondary	Assessment of patients social and behavioral conditions at different stages during the treatment		12 months